These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 12374519)

  • 21. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
    Targownik LE; Metge CJ; Leung S; Chateau DG
    Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges in managing NSAID-associated gastrointestinal tract injury.
    Goldstein JL
    Digestion; 2004; 69 Suppl 1():25-33. PubMed ID: 15001832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
    Goldstein JL; Huang B; Amer F; Christopoulos NG
    Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bleeding peptic ulcer in the elderly: risk factors and prevention strategies.
    Zullo A; Hassan C; Campo SM; Morini S
    Drugs Aging; 2007; 24(10):815-28. PubMed ID: 17896831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis.
    Ladabaum U; Chey WD; Scheiman JM; Fendrick AM
    Aliment Pharmacol Ther; 2002 Aug; 16(8):1491-501. PubMed ID: 12182749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand.
    Graham DY
    Am J Gastroenterol; 1996 Oct; 91(10):2080-6. PubMed ID: 8855725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
    Lanas A
    Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding.
    Edelson JT; Tosteson AN; Sax P
    JAMA; 1990 Jul; 264(1):41-7. PubMed ID: 2113103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?
    Elliott RA; Hooper L; Payne K; Brown TJ; Roberts C; Symmons D
    Rheumatology (Oxford); 2006 May; 45(5):606-13. PubMed ID: 16368733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastrointestinal injury from NSAID therapy. How to reduce the risk of complications.
    Lanas A
    Postgrad Med; 2005 Jun; 117(6):23-8, 31. PubMed ID: 16001765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis.
    Al MJ; Michel BC; Rutten FF
    Pharmacoeconomics; 1996 Aug; 10(2):141-51. PubMed ID: 10163417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of NSAID-associated peptic ulcer disease.
    Melcarne L; García-Iglesias P; Calvet X
    Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):723-33. PubMed ID: 26775657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
    You JH; Lee KK; Chan TY; Lau WH; Chan FK
    Aliment Pharmacol Ther; 2002 Dec; 16(12):2089-96. PubMed ID: 12452942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mucosa protective therapy with long-term nonsteroidal antirheumatic drugs].
    Cozzarini W; Rath J; Bauer A; Györög I; Györög M; Prenner M; Trianto T; Maderbacher H; Höller E; Grusch B; Sebesta C
    Wien Med Wochenschr; 2003; 153(13-14):295-303. PubMed ID: 12924104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
    Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
    Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What is the best strategy for diagnosis and treatment of Helicobacter pylori in the prevention of recurrent peptic ulcer bleeding? A cost-effectiveness analysis.
    Gené E; Sanchez-Delgado J; Calvet X; Gisbert JP; Azagra R
    Value Health; 2009; 12(5):759-62. PubMed ID: 19490560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of nonsteroidal anti-inflammatory drug-related peptic ulcer bleeding.
    Sung JJ
    Am J Med; 2001 Jan; 110(1A):29S-32S. PubMed ID: 11165993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs.
    Maetzel A; Ferraz MB; Bombardier C
    Arthritis Rheum; 1998 Jan; 41(1):16-25. PubMed ID: 9433865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prevention of Non-steroidal Anti-inflammatory Drug-induced Peptic Ulcers].
    Chu SJ; Yoon KT; Kim JS
    Korean J Gastroenterol; 2020 Nov; 76(5):232-237. PubMed ID: 33234769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.